Milton Packer
Columbia University Irving Medical Center
6 papers in the Anchorcite directory, published between 1992 and 2021, cited 33,284 times in total.
ORCID profileResearch topics
- Heart Failure Treatment and Management · 6 papers
- Renin-Angiotensin System Studies · 2 papers
- Heart rate and cardiovascular health · 2 papers
- Diabetes Treatment and Management · 2 papers
- Cardiovascular Function and Risk Factors · 2 papers
- Cardiac Fibrosis and Remodeling · 1 paper
Frequent co-authors
- Jean Lucien Rouleau · 2 papers
- Stefan D. Anker · 2 papers
- Javed Butler · 2 papers
- Gerasimos S Filippatos · 2 papers
- Stuart Pocock · 2 papers
- Peter E. Carson · 2 papers
- James L. Januzzi · 2 papers
- Subodh Verma · 2 papers
Papers
- Angiotensin–Neprilysin Inhibition versus Enalapril in Heart FailureNew England Journal of Medicine · 2014 · 7,166 citations
BACKGROUND: We compared the angiotensin receptor-neprilysin inhibitor LCZ696 with enalapril in patients who had heart failure with a reduced ejection fraction. In previous studies, enalapril improved survival in such patients. METHODS: In this double-blind trial, we randomly assigned 8442 patients…
- Effect of Captopril on Mortality and Morbidity in Patients with Left Ventricular Dysfunction after Myocardial InfarctionNew England Journal of Medicine · 1992 · 5,925 citations
BACKGROUND: Left ventricular dilatation and dysfunction after myocardial infarction are major predictors of death. In experimental and clinical studies, longterm therapy with the angiotensin-converting--enzyme inhibitor captopril attenuated ventricular dilatation and remodeling. We investigated whether captopril could reduce morbidity and mortality…
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart FailureNew England Journal of Medicine · 2020 · 5,468 citations
BACKGROUNDSodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure in patients regardless of the presence or absence of diabetes.More evidence is needed regarding the effects of these drugs in patients across the broad spectrum of heart…
- Empagliflozin in Heart Failure with a Preserved Ejection FractionNew England Journal of Medicine · 2021 · 5,211 citations
BACKGROUND: Sodium-glucose cotransporter 2 inhibitors reduce the risk of hospitalization for heart failure in patients with heart failure and a reduced ejection fraction, but their effects in patients with heart failure and a preserved ejection fraction are uncertain. METHODS: In…
- Cardiac Resynchronization in Chronic Heart FailureNew England Journal of Medicine · 2002 · 4,880 citations
BACKGROUND: Previous studies have suggested that cardiac resynchronization achieved through atrial-synchronized biventricular pacing produces clinical benefits in patients with heart failure who have an intraventricular conduction delay. We conducted a double-blind trial to evaluate this therapeutic approach. METHODS: Four hundred…
- The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart FailureNew England Journal of Medicine · 1996 · 4,634 citations
BACKGROUND: Controlled clinical trials have shown that beta-blockers can produce hemodynamic and symptomatic improvement in chronic heart failure, but the effect of these drugs on survival has not been determined. METHODS: We enrolled 1094 patients with chronic heart failure in…
Metadata from OpenAlex (CC0).